Cargando…
Immunotherapy Combined with Metronomic Dosing: An Effective Approach for the Treatment of NSCLC
SIMPLE SUMMARY: Non-small cell lung cancer (NSCLC) claims almost 80% of the total lung cancer cases, with the late-stage disease having an estimated median survival time of up to five years. Patients with NSCLC benefit from traditional maximum tolerated dose (MTD) chemotherapy alone or combined with...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071233/ https://www.ncbi.nlm.nih.gov/pubmed/33920884 http://dx.doi.org/10.3390/cancers13081901 |